BackgroundHypermethylation of the promoter of the tumor suppressor gene RASSF1A silences its expression and has been found to be associated with advanced grade prostatic tumors. The DNA methyltransferase (DNMT) family of enzymes are known to be involved in the epigenetic silencing of gene expression, including RASSF1A, and are often overexpressed in prostate cancer. The present study demonstrates how mahanine, a plant-derived carbazole alkaloid, restores RASSF1A expression by down-regulating specific members of the DNMT family of proteins in prostate cancer cells.ResultsUsing methylation-specific PCR we establish that mahanine restores the expression of RASSF1A by inducing the demethylation of its promoter in prostate cancer cells. Furthermore, we show that mahanine treatment induces the degradation of DNMT1 and DNMT3B, but not DNMT3A, via the ubiquitin-proteasome pathway; an effect which is rescued in the presence of a proteasome inhibitor, MG132. The inactivation of Akt by wortmannin, a PI3K inhibitor, results in a similar down-regulation in the levels DNMT1 and DNMT3B. Mahanine treatment results in a decline in phospho-Akt levels and a disruption in the interaction of Akt with DNMT1 and DNMT3B. Conversely, the exogenous expression of constitutively active Akt inhibits the ability of mahanine to down-regulate these DNMTs, suggesting that the degradation of DNMT1 and DNMT3B by mahanine occurs via Akt inactivation.ConclusionsTaken together, we show that mahanine treatment induces the proteasomal degradation of DNMT1 and DNMT3B via the inactivation of Akt, which facilitates the demethylation of the RASSF1A promoter and restores its expression in prostate cancer cells. Therefore, mahanine could be a potential therapeutic agent for advanced prostate cancer in men when RASSF1A expression is silenced.

Germ cell apoptosis, which occurs normally during spermatogenesis, increases after testosterone withdrawal from the testis. The molecular mechanism by which this occurs remains uncertain. The Fas system has been implicated as a possible key regulator of apoptosis in various cells: binding of Fas ligand (FasL), a type II transmembrane protein, to Fas, a type I transmembrane receptor protein, triggers apoptosis in cells expressing Fas. Recently, Fas has been localized to germ cells, and FasL to Sertoli cells, within the rat testis. We hypothesized that Fas protein content would rise in response to reduced levels of testosterone as part of a suicide pathway that would result in germ cell apoptosis. To test this hypothesis, ethane 1,2-dimethanesulfonate (EDS), a Leydig cell toxicant, was used to kill Leydig cells and thus reduce intratesticular testosterone levels in Sprague Dawley rats. Apoptosis was examined in situ and biochemically, and Fas protein content in the testis was monitored by Western blot analysis. We show that EDS injection results in the following sequence of events: apoptotic death of Leydig cells by a mechanism that does not involve Fas; reduced testosterone; increased testicular Fas content; and germ cell apoptosis. These results suggest that Fas may play a role in the apoptotic death of germ cells that results from reduced intratesticular testosterone levels, and that testosterone may play a role in germ cell survival via its suppression of Fas.

We present a systematic and formal approach toward finding solitary wave solutions of non-linear evolution and wave equations f r c n the real exponential solutions of the underlying linear equations. The physical concept is one of the mixing of these elementary solutions through the non-linearities in the system. In the present paper the emphasis is, however, on the mathematical aspects, i.e. the formal procedure necessary to find single solitary wave solutions. By means of examples we show how various cases of pulse-type and kink-type solutions are to be obtained by this method. An exhaustive list of equations so treated is presented in tabular form, together with the particular intermediate relations necessary for deriving their solutions. We also outline the extension of our technique to construct N-soliton solutions and indicate connections with other existing methods.

It is well established that androgens are central to regulation of the growth of the mammalian prostate gland. Conversely, androgen deprivation by castration induces rapid cell death in the ventral prostate via an apoptotic mechanism. To date, most studies of cell death in the rodent prostate have focused on the ventral lobe, with little attention directed to the dorsal and lateral lobes. The results presented herein demonstrate that cell death in the rat prostate gland caused by castration is lobe specific. In particular, castration caused decreases in wet weights and protein contents of all three prostatic lobes, but these events were more rapid and profound in the ventral than in the dorsal and lateral lobes. Reduced epithelial cell size was apparent in the three lobes as well. However, castration resulted in loss of DNA content in the ventral lobe only. To confirm this finding, and to examine apoptosis of individual cells, we used in situ labeling of fragmented DNA, supported by biochemical analysis of DNA integrity in agarose gels. With both approaches, significant cell death in response to castration was seen in the ventral lobe but not the dorsal and lateral lobes. Taken together, these results clearly indicate that there are lobe-specific differences in the response of the rat prostate to androgen ablation by castration, with apoptotic cell death occurring in the ventral lobe of the prostate but to a far lesser extent, if at all, in the dorsal and lateral lobes. Moreover, castration caused apoptotic death of both epithelial and stromal cells of the ventral prostate, with these cells dying throughout the ductal network of the ventral prostate rather than being restricted to a particular region. We suggest that lobe-specific differences in androgen responsiveness in the rat prostate may provide an appropriate model for the study of androgen-independent prostatic cell survival during tumor progression.

Considered a chemopreventive agent, the ability of genistein to modulate the progression of existing prostate cancer (CaP) is not clear. We show here that the consumption of genistein (250 mg/kg diet) by 12-week-old transgenic adenocarcinoma mouse prostate (TRAMP-FVB) mice harboring prostatic intraepithelial neoplasia lesions until 20 weeks of age induces an aggressive progression of CaP, as evidenced by a 16% increase in the number of well-differentiated and poorly differentiated prostates, coinciding with a 70% incidence of pelvic lymph node (LN) metastases as opposed to 0% and 10% in 0 and 1,000 mg/kg groups, concomitant with elevated osteopontin (OPN) expression in prostates and LNs. Equivalent nanomolar (500 nmol/L) concentrations of genistein recapitulated these effects in human PC3 CaP cells as evidenced by increased proliferation, invasion, and matrix metalloproteinase-9 (MMP-9) activity (f2-fold), accompanied by an up-regulation of OPN expression and secretion, compared with vehicletreated cells. A pharmacologic dose (50 Mmol/L) decreased proliferation, invasion, and MMP-9 activity (>2.0-fold) concomitant with OPN reduction. Upon OPN knockdown by short hairpin RNA, genistein was no longer effective in upregulating PC3 cell proliferation, invasion, and MMP-9 activation, which were significantly reduced in the absence of OPN, highlighting the requirement for OPN in mediating the effects of genistein. Proliferation, invasion, and OPN levels were also nonsignificantly induced by genistein in the presence of ICI 182,780 or wortmannin, indicating a dependence on phosphatidylinositol 3-kinase and estrogen signaling. Our results suggest the presence of a biphasic regulation of CaP growth and metastasis by genistein, warranting careful examination of the effects of genistein on hormone-dependent cancers in a chemotherapeutic setting. [Cancer Res 2009;69(8):3695-703]